PubMed Health⌕ Search

Biomedical subjects

N Olivier

Publications and source records attributed to N Olivier.

5 recordsLinked to original sources
PubMed2006

[Preliminary study of cardiorespiratory decondittioning in athletes after anterior cruciate ligament reconstruction].

AIM: The aim of this study was to analyze changes in cardiorespiratory fitness of athletes who had surgery following a lesion of the anterior cruciate ligament of the knee. METHODS: Two groups of 12 athletes at the regional level underwent surgical repair to rebuild the external anterior crossed ligament of the knee (central third bone patellar tendon bone autograft and doubled semitendinosus/doubled gracilis autograft techniques). All subjects were evaluated before and after surgery within 7 days: the first group underwent maximal incremental tests with the upper limbs, and the second group measurement of resting cardiac volumes. RESULTS: Surgery followed by a few days of confinement generated a quick and significant reduction in the maximal oxygen consumption (-7%, P<0.05) and peak aerobic power (-8%, P<0.05). End diastolic volume and stroke volume were reduced, by 23% and 27% respectively (P<0.05). A significant reduction of ejection fraction was also observed (P<0.05). The mean left ventricular ejection fraction was 65% before the surgery 60% after 7 days' of hospitalization. CONCLUSION: In sportsmen, 7 days of hospitalization due to surgery of the knee led to resting cardiac unsuitability characterized by a significant reduction in the stroke volume. These elements could involve decreased aerobic fitness and should encourage the hospital practitioner to propose a program of aerobic training in addition to conventional rehabilitation.

Adaptation, Physiological↗
PubMed2002

Orally active iron chelators.

In patients with transfusion-dependent anemias, iron accumulation is fatal in the absence of chelating therapy. Extended survival, free of most complications of iron overload is observed in patients treated with early, adequate parenteral deferoxamine. Despite its success in prevention and treatment of iron toxicity, the expense and inconvenience of this therapy have stimulated a continued quest for an effective chelating agent that is orally active. Unfortunately, studies emerging over the last five years have confirmed that the most widely administered orally active agent, deferiprone (L1; 1,2-dimethyl-3-hydropyrid-4-one) may be harmfully ineffective in many patients: 18-65% of patients in six studies which obtained hepatic irons after long term deferiprone treatment had body iron exceeding the threshold for cardiac disease and premature death. The impact of deferiprone on cardiac and liver disease must be evaluated further, while the association between deferiprone and accelerated hepatic fibrosis still awaits refutation in large prospective trials. In view of the striking therapeutic successes of deferoxamine over the past 20 years, administration of deferiprone outside the setting of prospective clinical trials may need to be reconsidered. Meanwhile, an orally active iron chelator of demonstrated safety and effectiveness remains an objective for development for transfused patients.

Administration, Oral↗
PubMed1982

Efficacy and safety of aerosolized triamcinolone acetonide in steroid-dependent and steroid-independent chronic asthmatic patients.

Fourteen steroid-dependent and 16 steroid-independent asthmatic patients received aerosol triamcinolone acetonide for 12 weeks (two 200-micrograms inhalations four times daily). The mean daily oral steroid dose for the steroid-dependent patients was reduced from 12.5 mg at baseline to 1.34 mg after 12 weeks of aerosol therapy. In both groups of patients, FEV1.0, FVC and FEF25-75% values improved during therapy, usually at a statistically significant rate. Highly significant improvement occurred in shortness-of-breath, wheezing tightness-in-chest, and cough symptoms in all patients. However, changes in serum cortisol levels were not statistically significant. Side effects included transient hoarseness (seven patients), dry throat (one), and sore throat (one). No oral candidiasis was observed and no patient discontinued therapy because of side effects. Steroid withdrawal symptoms, which gradually abated, were experienced by half of the steroid-dependent patients. Aerosolized triamcinolone acetonide was therefore considered a safe and effective modality in the management of chronic asthma.

Adolescent↗